Q2 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at HC Wainwright boosted their Q2 2025 earnings estimates for shares of Eton Pharmaceuticals in a report issued on Monday, January 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.08 per share for the quarter, up from their previous estimate of $0.07. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals' FY2025 earnings at $0.38 EPS and FY2026 earnings at $0.84 EPS.

Separately, Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday.

Eton Pharmaceuticals Stock Up 0.2 %

NASDAQ:ETON traded up $0.02 during trading hours on Thursday, reaching $12.01. 322,296 shares of the company's stock were exchanged, compared to its average volume of 259,796. The firm has a market capitalization of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The company has a 50-day moving average of $11.64 and a 200 day moving average of $7.35.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new stake in Eton Pharmaceuticals during the second quarter worth about $3,095,000. Westside Investment Management Inc. boosted its stake in shares of Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock worth $3,711,000 after acquiring an additional 33,275 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock worth $1,637,000 after acquiring an additional 32,365 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company's stock worth $1,561,000 after acquiring an additional 7,029 shares during the period. Finally, Wasatch Advisors LP purchased a new position in Eton Pharmaceuticals in the 3rd quarter valued at approximately $1,431,000. Institutional investors and hedge funds own 27.86% of the company's stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.